Is CLDI (CLDI) Halal?

AMEX Healthcare United States $3M
✗ NOT HALAL
Confidence: 90/100
CLDI (CLDI) is Not Halal under AAOIFI Standard 21. The company's debt ratio of 272.1% exceeds the 30% threshold, indicating excessive interest-bearing debt relative to market capitalization. CLDI operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 272.1%
/ 30%
371.0%
/ 30%
0.0%
/ 30%
N/A ✗ NOT HALAL
DJIM 272.1%
/ 33%
371.0%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
MSCI 49.6%
/ 33%
67.6%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
S&P 272.1%
/ 33%
371.0%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
FTSE 49.6%
/ 33%
67.6%
/ 33%
0.0%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

P/E Ratio
0.8
Forward: -0.3
EPS
$0.36
P/B Ratio
0.3
EV/EBITDA
0.2
EV: -$5M
Revenue
$0
Beta
1.1
Average volatility
Current Ratio
2.1

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Assets (ROA) -119.6%

Cash Flow & Balance Sheet

Operating Cash Flow-$20M
Free Cash Flow-$20M
Total Debt$7M
Debt-to-Equity46.0
Current Ratio2.1
Total Assets$14M

Price & Trading

Last Close$0.28
50-Day MA$0.70
200-Day MA$2.28
Avg Volume198K
Beta1.1
52-Week Range
$0.26
$19.20

About CLDI (CLDI)

CEO
Dr. Eric E. Poma Ph.D.
Employees
28
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
AMEX
Market Cap
$3M
Currency
USD

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301 for multiple indications, which is in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors. The company also offers oncolytic virus platforms, such as NeuroNova, SuperNova, and RTNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is CLDI (CLDI) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), CLDI is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is CLDI's debt ratio?

CLDI's debt ratio is 272.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 49.6%.

What are CLDI's key financial metrics?

CLDI has a market capitalization of $3M, trailing P/E ratio of 0.8.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.